Genenta Science SpA ADR(GNTA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:04 PM ET (Korea 9/12 05:04)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.37 | Insider Own | - | Shs Outstand | 23.4M | Perf Week | -11.54% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | - | Perf Month | -35.32% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 5.88% | Short Float | - | Perf Quarter | -56.21% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | -11.88% | Short Ratio | 1.04 | Perf Half Y | -2.8% |
| Sales | 0.00B | P/B | 0.77 | EPS next 5Y | - | ROA | -27.77% | Short Interest | 0.13M | Perf YTD | -43.57% |
| Book/sh | 1.09 | P/C | 0.6 | EPS past 3/5Y | 8.56% -1.23% | ROE | -38% | 52W High | -91.59% ($10.00) | Perf Year | -69.43% |
| Cash/sh | 1.41 | P/FCF | - | Sales past 3/5Y | - | ROIC | -21.2% | 52W Low | 52.87% ($0.55) | Perf 3Y | -85.72% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 29.62% | Gross Margin | - | Volatility(W/M) | 10.4% 7.8% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.1 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 14.16 | EPS Q/Q | 48.49% | Profit Margin | - | RSI (14) | 26.85 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 14.16 | Sales Q/Q | - | SMA20 | -21.07% ($1.06) | Beta | 0.74 | Target Price | $6.94 |
| Payout | - | Debt/Eq | 0.35 | Earnings | 2026/7/22 | SMA50 | -35.7% ($1.31) | Rel Volume | 0.26 | Prev Close | $0.86 |
| Employees | 9 | LT Debt/Eq | 0.35 | EPS/Sales Surpr. | - | SMA200 | -29.59% ($1.19) | Avg Volume(3M) | 0.12M | Price | $0.84 |
| IPO | 2021/12/15 | Option/Short | No/Yes | Trades | 113 | Volume | 31,919 | Change | -2.38% |
Company
GNTA is a Industrials sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Genenta Science () is a clinical-stage immuno-oncology biotech headquartered in Italy. The company develops its lead candidate, <strong>Temferon™</strong>, which genetically modifies a patient's hematopoietic stem cells to trigger an immune response within the tumor microenvironment, with solid tumors such as glioblastoma and metastatic renal cell carcinoma as its primary targets.
Over the past 1 year, on the lower side
92% below its 1-year high.
GNTA has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
The stock looks undervalued
Trading at - times earnings.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -85.7% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 5.9%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $20M.
GNTA $20M PER -
MMM $85B PER 29.3
HON $64B PER 7.5
VMI $9B PER 18.8
FAQ
What kind of company is GNTA?
GNTA belongs to the Industrials sector and operates in the Conglomerates industry.
What is the market cap of GNTA?
The market cap of GNTA is approximately $20M, ranking 5,290 within its sector.
What is the 52-week high and low for GNTA?
GNTA has recorded a 52-week high of $10.00 and a low of $0.55.
